Drugs / C5252
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05095441 | Mar → Apr 2023 | glioblastoma | ImmVira Pharma Co. Ltd | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07243340 | Dec 2025 → Dec 2027 expected | malignant glioma | ImmVira Pharma Co. Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C5252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07243340 ↗ |
| Known as | MVR-C5252 | “A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma” NCT05095441 ↗ |
| Route | Other | “a single intratumoral (IT) injection of C5252” NCT05095441 ↗ |